New Research Confirms No Link Between Maternal mRNA COVID-19 Vaccination and Neurodevelopmental Disorders in Toddlers

New data presented at the 2026 Pregnancy Meeting of the Society for Maternal-Fetal Medicine (SMFM) has provided significant reassurance to expectant parents regarding the safety of COVID-19 immunization. The study, which focused on the neurodevelopmental outcomes of children born to vaccinated mothers, found no evidence of an association between receiving an mRNA COVID-19 vaccine during or shortly before pregnancy and the subsequent development of autism or other developmental delays. This research, conducted by the Maternal-Fetal Medicine Units (MFMU) Network and funded by the National Institutes of Health (NIH), serves as a critical addition to the growing body of evidence supporting the safety profile of maternal vaccinations.

The Scope and Methodology of the MFMU Study

The study, titled "Association between SARS-CoV-2 vaccine in pregnancy and child neurodevelopment at 18-30 months," employed a prospective, multi-center, observational framework. Between May 2024 and March 2025, researchers tracked 434 children to evaluate their developmental progress during their toddler years. By selecting a cohort of children aged 18 to 30 months, the researchers were able to utilize standardized screening tools to identify potential neurodevelopmental hurdles that often manifest during this window of early childhood.

The research team divided the participants into two strictly matched groups: 217 children whose mothers received at least one dose of an mRNA COVID-19 vaccine during pregnancy or within 30 days of conception, and 217 children born to mothers who remained unvaccinated during that same period. To ensure the integrity of the data and minimize confounding variables, the researchers employed a rigorous matching process. Pairs were aligned based on demographic and clinical indicators, including race, insurance status, delivery location, and date of birth. Furthermore, the study excluded pregnancies that resulted in multiple births, those that ended prior to 37 weeks gestation, or cases involving children with major congenital malformations, thereby isolating the variable of maternal vaccination as precisely as possible.

Measuring Neurodevelopmental Milestones

The assessment of the children involved a multi-faceted approach to developmental monitoring. The primary instrument used was the Ages and Stages Questionnaire (ASQ-3), a validated screening tool that evaluates five critical domains: communication, gross motor skills, fine motor skills, problem-solving, and personal-social interaction. To ensure a comprehensive overview of the children’s health, the researchers also incorporated data from the Modified Checklist for Autism in Toddlers (M-CHAT), the Child Behavior Checklist, and the Early Childhood Behavior Questionnaire.

By applying these standardized metrics, the research team sought to determine whether any divergence in developmental trajectories existed between the two cohorts. The results indicated no statistically significant difference in outcomes between the children of vaccinated mothers and those of unvaccinated mothers. This finding is particularly notable given the breadth of the developmental areas covered, suggesting that the protection provided by the vaccine to the mother does not interfere with the complex neurological maturation of the fetus.

Clinical Context and Public Health Guidelines

In the United States, the current public health landscape features two primary categories of COVID-19 vaccines: mRNA vaccines, such as those developed by Pfizer-BioNTech and Moderna, and protein subunit vaccines. Since the initial rollout of these vaccines, health authorities—including the Centers for Disease Control and Prevention (CDC) and the American College of Obstetricians and Gynecologists (ACOG)—have consistently emphasized the safety of these products during pregnancy.

Pregnancy is known to alter the immune system, making expectant individuals more susceptible to severe complications from respiratory viruses. COVID-19, in particular, has been linked to an increased risk of preterm birth, preeclampsia, and maternal respiratory distress. Consequently, the recommendation for vaccination is rooted in a risk-benefit analysis that prioritizes the health of both the birthing parent and the infant. By providing data on the long-term neurodevelopmental health of children, this new study addresses one of the most frequently cited concerns among hesitant parents, potentially improving vaccine uptake in this vulnerable demographic.

Expert Perspectives on the Findings

Dr. George R. Saade, senior researcher and Professor and Chair of Obstetrics and Gynecology at the Macon & Joan Brock Virginia Health Sciences at Old Dominion University, noted the importance of the study’s clarity. "Neurodevelopment outcomes in children born to mothers who received the COVID-19 vaccine during or shortly before pregnancy did not differ from those born to mothers who did not receive the vaccine," Dr. Saade stated. His remarks underscore the objective nature of the research, which relied on clinical observation rather than theoretical modeling.

Echoing this sentiment, Dr. Brenna L. Hughes of Duke University highlighted the rigor of the investigative process. "This study, conducted through a rigorous scientific process in an NIH clinical trials network, demonstrates reassuring findings regarding the long-term health of children whose mothers received COVID-19 vaccination during pregnancy," said Dr. Hughes. The involvement of the Eunice Kennedy Shriver National Institute of Child Health and Human Development underscores the institutional commitment to transparency and evidence-based medicine in maternal health.

Broader Implications for Maternal-Fetal Medicine

The publication of these findings in the February 2026 issue of PREGNANCY, the official journal of the SMFM, is expected to have a lasting impact on clinical practice. For obstetricians and gynecologists, the study provides a robust data point to share with patients during prenatal consultations. Addressing concerns about neurodevelopment—specifically autism—has been a persistent challenge for clinicians, as misinformation regarding vaccines and autism has historically hindered public health efforts.

The study’s findings also illustrate the importance of prospective, observational research in the post-pandemic era. While early studies were focused on the immediate clinical impact of COVID-19 infection and vaccination, the focus has now shifted to the longitudinal health of children exposed to these medical interventions in utero. As the medical community continues to monitor these cohorts, the consistency of these findings will be essential in maintaining public trust in immunization programs.

Addressing Vaccine Hesitancy

Despite the overwhelming consensus from the global scientific community regarding vaccine safety, vaccine hesitancy remains a factor in obstetric care. Many expectant parents report that their primary concern is not the immediate safety of the vaccine for themselves, but rather the potential for unknown, long-term developmental impacts on their child. By evaluating children up to 30 months of age—a period during which early markers of developmental delays often become visible—the MFMU Network has provided a specific answer to this concern.

The methodology of the study, which strictly controlled for demographic factors and medical history, ensures that the findings are not skewed by socio-economic or environmental variables that might otherwise impact childhood development. This granular approach allows clinicians to communicate the findings with a higher degree of confidence.

Future Research Directions

While the findings from the 2026 SMFM meeting are definitive for the studied age group, experts emphasize that continued surveillance is necessary. The MFMU Network and other similar research bodies are expected to continue tracking children born to vaccinated mothers as they reach school age. Such studies will be instrumental in identifying any subtle developmental variations that might not be detectable in early childhood, although current medical consensus remains optimistic that no such associations exist.

Furthermore, the integration of this data into electronic health records and national databases will allow for larger-scale retrospective studies in the coming years. By combining the precision of the current study with the breadth of population-wide data, the medical community will be even better equipped to provide comprehensive counseling to future generations of parents.

Conclusion and Official Disclosure

The findings presented at the 2026 Pregnancy Meeting represent a milestone in the ongoing assessment of COVID-19 vaccination in pregnancy. By demonstrating a clear lack of association between maternal mRNA vaccination and neurodevelopmental disorders, the study provides a stable foundation for clinical guidelines and patient counseling.

It is important to note, as the researchers have indicated, that the conclusions and interpretations presented in this study are those of the authors and do not necessarily reflect the official policy or position of the National Institutes of Health. This distinction is standard in scientific publishing, intended to preserve the independence of peer-reviewed research. As the medical community moves forward, the evidence presented by the MFMU Network will likely serve as a cornerstone for addressing parental concerns and ensuring that maternal health remains a primary focus of global immunization strategies. The study stands as a testament to the value of continued, evidence-based inquiry in protecting the health of the next generation.